NYSE - Delayed Quote • USD
Merck & Co., Inc. (MRK)
At close: April 26 at 4:00 PM EDT
After hours: April 26 at 7:50 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 17 | 17 | 24 | 24 |
| Avg. Estimate | 2.14 | 2.36 | 8.58 | 9.85 |
| Low Estimate | 1.85 | 2.21 | 8.45 | 9.3 |
| High Estimate | 2.22 | 2.49 | 8.96 | 10.5 |
| Year Ago EPS | -2.06 | 1.94 | 1.51 | 8.58 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 15 | 14 | 24 | 24 |
| Avg. Estimate | 15.88B | 16.67B | 63.94B | 68.32B |
| Low Estimate | 15.53B | 16.36B | 63B | 66.08B |
| High Estimate | 16.34B | 16.96B | 65B | 71.03B |
| Year Ago Sales | 15.04B | 14.56B | 60.12B | 63.94B |
| Sales Growth (year/est) | 5.60% | 14.50% | 6.40% | 6.90% |
Earnings History
| CURRENCY IN USD | 6/30/2023 | 9/30/2023 | 12/31/2023 | 3/31/2024 |
|---|---|---|---|---|
| EPS Est. | -2.18 | 1.78 | -0.11 | 1.87 |
| EPS Actual | -2.06 | 1.94 | 0.03 | 2.07 |
| Difference | 0.12 | 0.16 | 0.14 | 0.2 |
| Surprise % | 5.50% | 9.00% | 127.30% | 10.70% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 2.14 | 2.36 | 8.58 | 9.85 |
| 7 Days Ago | 2.11 | 2.37 | 8.56 | 9.8 |
| 30 Days Ago | 2.02 | 2.38 | 8.57 | 9.77 |
| 60 Days Ago | 2.01 | 2.38 | 8.58 | 9.76 |
| 90 Days Ago | 2.06 | 2.26 | 8.49 | 9.56 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Jun 2024) | Next Qtr. (Sep 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 6 | 3 | 7 | 6 |
| Up Last 30 Days | 10 | 4 | 14 | 14 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 3 | 6 | 1 | -- |
Growth Estimates
| CURRENCY IN USD | MRK | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 203.90% | -- | -- | 5.40% |
| Next Qtr. | 21.60% | -- | -- | 10.90% |
| Current Year | 468.20% | -- | -- | 4.50% |
| Next Year | 14.80% | -- | -- | 13.10% |
| Next 5 Years (per annum) | 67.38% | -- | -- | 10.94% |
| Past 5 Years (per annum) | -11.64% | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Truist Securities: Buy to Buy | 4/26/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/18/2024 |
| Maintains | Berenberg: Buy to Buy | 4/8/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/5/2024 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/1/2024 |
| Reiterates | Truist Securities: Buy to Buy | 3/28/2024 |
Related Tickers
BMY Bristol-Myers Squibb Company
44.85
+0.34%
ABBV AbbVie Inc.
159.62
-4.58%
PFE Pfizer Inc.
25.40
+0.55%
JNJ Johnson & Johnson
146.14
-0.46%
LLY Eli Lilly and Company
733.51
+1.19%
GILD Gilead Sciences, Inc.
65.42
+0.23%
AZN AstraZeneca PLC
75.17
+0.19%
BIIB Biogen Inc.
208.90
+3.18%
AMGN Amgen Inc.
269.98
+0.22%
NVS Novartis AG
97.44
-1.64%